Table S1 from A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation–Positive Solid Tumors
Mark W. Kieran(Children Cancer Hospital), James A. Whitlock(Hospital for Sick Children), Alberto Broniscer(St Nicholas Hospital), Trent R. Hummel(Cincinnati Children's Hospital Medical Center), Birgit Geoerger(Inserm), Anne‐Isabelle Bertozzi(Université Fédérale de Toulouse Midi-Pyrénées), Kenneth J. Cohen(Hospital for Sick Children), Andrew D.J. Pearson(Pearson (United Kingdom)), Mark W. Russo, Pooja Hingorani(Center for Cancer and Blood Disorders), Ira J. Dunkel(Memorial Sloan Kettering Cancer Center), Éric Bouffet(Hospital for Sick Children), Christine A. Pratilas(Johns Hopkins University), Noelia Nebot(Research Triangle Park Foundation), Steve Green(Plant & Food Research), Lillian Tseng(Tris Pharma (United States)), Isabelle Aerts(Université Paris Sciences et Lettres), Violet Shen(Ruhr University Bochum), Darren Hargrave(Great Ormond Street Hospital)
Cited by 0
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Medulloblastoma Comprises Four Distinct Molecular Variants
|Journal of Clinical Oncology|2010|1.4k
BRAF mutation predicts sensitivity to MEK inhibition
|Nature|2005|1.3k